TG Therapeutics, Inc. (NASDAQ: TGTX) is a commercial-stage biopharmaceutical company whose lead product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved for relapsing forms of multiple sclerosis. Because TGTX is a stock with multiple current, attributed targets, analyst estimates are the primary input for the central target here.
Seven recent, verifiable price targets were reviewed: TD Cowen at $75 (Nov. 9, 2026), H.C. Wainwright at $78 (Sept. 21, 2026), B. Riley Securities at $86 (Sept. 2, 2026), Jefferies at $83 (July 14, 2026), J.P. Morgan at $72 (Aug. 7, 2026), Goldman Sachs at $41 (June 4, 2026), and Bank of America at $21 (Aug. 5, 2026). The range is unusually wide, from $21 to $86.
The overall mean of those seven targets is about $65, only marginally above the latest price. Because that mean fails to clear the 10% minimum-distance threshold, the central target is instead the average of the five targets above the current price, which calculates to $78.80 and rounds to $79. The full context—a roughly $65 overall mean and a $21–$86 range—shows genuine disagreement rather than a tidy "analyst consensus."
The divide is stark. Bullish analysts emphasize accelerating BRIUMVI revenue and a future subcutaneous formulation, while Bank of America maintains a Sell and a $21 target on competitive and valuation concerns, and Goldman Sachs holds a Neutral rating with a $41 target.
With the stock near $63.36, reaching $79 implies an upside of roughly 25%, a substantial move. The shares have climbed sharply from a 52-week low near $27, now trading above prior 52-week highs—a sign of strong momentum but also a setup where expectations are already elevated.
Fundamentally, the path depends on sustained BRIUMVI demand and earnings per share (EPS) growth. The company's most recent quarterly report showed revenue of about $259.9 million, exceeding estimates, alongside EPS of $0.35 that narrowly missed. Full-year 2026 revenue guidance has been raised toward approximately $950 million. A 25% move is not trivially small, but it is within the range implied by the bullish half of the analyst group.
The stock has broken above its prior 52-week high, which can now act as a reference point, while the broader multi-month range from roughly $27 to the low-$60s shows how far the shares have traveled. A decisive hold above former highs would support the bullish technical case, whereas a retreat back below them would suggest the breakout is fading. The $79 target sits well above recent consolidation, so reaching it would require a sustained leg higher rather than a routine move.
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms vary. Key items to watch include quarterly BRIUMVI sales and any updates to full-year guidance, EPS trends, developments on the subcutaneous program, competitive launches or data readouts, and further analyst revisions. Regulatory and reimbursement decisions tied to BRIUMVI's expansion would also matter.
For traders who want a data-driven, always-on view of changing conditions, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals from shifting market behavior, technical patterns, and AI-driven analysis. The tool is designed to help investors discover opportunities, monitor existing positions, and spot evolving trends more efficiently than manual screening allows. It does not replace independent judgment, but it can add a systematic layer to the decision-making process.
Can TGTX reach $79? The target is achievable only if the bullish half of the analyst community is right. That group's average objective of $79 requires roughly a 25% advance, backed by BRIUMVI's commercial momentum and a potential subcutaneous catalyst. Against that, a $21 Sell target from Bank of America and a $41 Hold from Goldman Sachs underscore how divergent the Street's views are. With an overall mean near $65 and an extremely wide $21–$86 range, this is not a case of broad agreement. Investors should weigh the product's execution record against competitive and valuation risks, and watch upcoming earnings and guidance updates before drawing any conclusion.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, TGTX has been loosely correlated with ARQT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if TGTX jumps, then ARQT could also see price increases.
| Ticker / NAME | Correlation To TGTX | 1D Price Change % | ||
|---|---|---|---|---|
| TGTX | 100% | +1.39% | ||
| ARQT - TGTX | 43% Loosely correlated | +4.52% | ||
| EXEL - TGTX | 39% Loosely correlated | -1.62% | ||
| PTGX - TGTX | 38% Loosely correlated | +0.26% | ||
| KRYS - TGTX | 38% Loosely correlated | +1.14% | ||
| INCY - TGTX | 37% Loosely correlated | -1.30% | ||
More | ||||